Core Viewpoint - The company has established a strategic partnership with Crescent Biopharma to jointly develop and commercialize cancer treatment methods, including novel combination therapies [1][2]. Group 1: Partnership Details - The collaboration involves the company's antibody-drug conjugate (ADC) SKB105, which targets integrin β6, and Crescent's bispecific antibody CR-001, which targets PD-1 and VEGF, both aimed at treating solid tumors [1][2]. - The partnership grants Crescent exclusive rights to research, develop, manufacture, and commercialize SKB105 outside of the Greater China region, while the company receives exclusive rights for CR-001 in the Greater China region [2]. Group 2: Financial Terms - The company will receive an upfront payment of $80 million from Crescent, with potential milestone payments of up to $1.25 billion and tiered royalties based on SKB105's net sales [2]. - Crescent will pay the company an upfront fee of $20 million, with milestone payments of up to $30 million and tiered royalties based on CR-001's net sales [2]. Group 3: Strategic Benefits - The board believes the partnership aligns with the best interests of the company and its shareholders, enhancing the differentiated oncology R&D pipeline and advancing the global development of SKB105 [3]. - The collaboration aims to leverage both parties' resources to explore new single-agent and combination therapy strategies in oncology, maximizing the therapeutic potential of both candidates in China and globally [3].
科伦博泰生物-B与Crescent Biopharma建立战略合作伙伴关系，共同开发和商业化肿瘤治疗手段